Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales in the domestic business increased due to growth in prescriptions related to edema, headaches and dizziness, information-provision activities for healthcare professionals, and an increase in the number of stores handling healthcare products. Sales in the China business increased due to the consolidation of 上海虹橋中薬飲片有限公司 and growth in sales of crude drug materials and prepared herbal medicines. Ordinary profit increased due to foreign exchange gains on loans to overseas subsidiaries.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥49,704 million (YoY +15.3%) |
| Operating profit | ¥7,881 million (YoY +2.1%) |
| Ordinary income | ¥9,753 million (YoY +57.8%) |
| Profit attributable to owners of the parent | ¥6,457 million (YoY +47.8%) |
| Net income per share | ¥86.63 |
| Equity ratio | End of the current fiscal period 54.3% / End of previous period 54.3% |
| Total assets | ¥602,148 million |
| Net assets | ¥378,846 million |
| Cash flows from operating activities | ¥-4,444 million |
| Cash flows from investing activities | ¥-10,771 million |
| Cash flows from financing activities | ¥6,611 million |
| Cash and cash equivalents at end of period | ¥71,205 million |
| Full-year earnings forecast | Net Sales ¥213,600 million (YoY +10.9%) / Operating profit ¥37,500 million (YoY +6.5%) / Ordinary income ¥35,500 million (YoY -11.3%) / Net income ¥26,200 million (YoY -6.8%) |
| Annual Dividend Forecast | ¥147 → ¥158（+7.5%） |
| Regional sales | ¥41,475 million (YoY +6.7%), ¥8,228 million (YoY +94.8%) |
| Depreciation and amortization | ¥3,427 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥19 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥11 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 76,758,362 |
| Treasury Shares at Period-End | 2,212,210 |
| Factors Behind Changes in Business Performance | Sales in the domestic business increased due to growth in prescriptions related to edema, headaches and dizziness, information-provision activities for healthcare professionals, and an increase in the number of stores handling healthcare products. Sales in the China business increased due to the consolidation of 上海虹橋中薬飲片有限公司 and growth in sales of crude drug materials and prepared herbal medicines. Ordinary profit increased due to foreign exchange gains on loans to overseas subsidiaries. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the domestic business, sales of ethical Kampo medicines increased on growth in prescriptions related to edema, headaches and dizziness, as well as information-provision activities tailored to the needs of healthcare professionals. Healthcare product sales increased as the number of stores handling the products expanded. Sales in the China business also increased, reflecting the consolidation of 上海虹橋中薬飲片有限公司 and growth in sales of crude drug materials and prepared herbal medicines. Operating profit was affected by foreign exchange movements and a higher cost-of-sales ratio resulting from the increased sales contribution of the China business, while ordinary profit increased due to foreign exchange gains on loans to overseas subsidiaries.